Hanmi Pharmaceutical announced on March 18 that it will unwrap 10 new research projects, the most in the industry, in the American Association for Cancer Research 2024 (AACR 2024), which will run in San Diego of the United States from April 5 to 10.First, Hanmi Pharmaceutical will present the result
Kolon Life Science announced on March 11 that its osteoarthritis cell and gene therapy “TG-C,” developed by Kolon TissueGene, has been granted a patent in Japan. The patent is for a “pharmaceutical composition for the prevention or treatment of osteoarthritis” related to TG-C. TG-C is a medication t
JW Pharmaceutical announced on Feb. 26 that it has signed a joint research agreement with its subsidiary, C&C Pharmaceuticals Research Institute, for the development of innovative anti-cancer cell therapies.According to the agreement, JW Pharmaceutical will develop a new CAR-NK cell therapy targetin
Samsung Bioepis announced on Feb. 25 that it has obtained a positive opinion for the sale of its biosimilar of Stelara, known as Pyzchiva, from the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA).The original drug of Pyzchiva developed by Janssen, know
Samsung Biologics has announced a collaboration with LegoChem Biosciences for the development of Antibody-Drug Conjugate (ADC) therapeutics.On Feb.7, Samsung Biologics revealed it had entered into a new Contract Development Organization (CDO) agreement with LegoChem Biosciences (hereinafter referred
Celltrion announced on Feb. 6 that Rani Therapeutics (Rani) in the United States has confirmed positive topline results in the Phase 1 clinical trial of oral ustekinumab (development name: RT-111). RT-111 is an oral formulation of Celltrion’s Stelara biosimilar, CT-P43, currently under development.I
Daewoong Pharmaceutical announced on Jan. 30 that its partner, AEON Biopharma, presented the Phase 2 clinical trial results and preclinical PTSD data of Daewoong’s botulinum toxin ABP-450 at the TOXINS 2024 conference. TOXINS 2024, a significant conference on neurotoxins, took place in Berlin, Germa
Kang Stem Biotech announced on Jan. 24 that it received final approval from the Japanese Ministry of Health, Labour and Welfare on Jan. 23 for its application for recognition of the manufacture of specific cell processed products.Through this approval, the company will receive adipose tissue from pa
Celltrion announced on Jan. 24 that it has signed a memorandum of understanding with WuXi XDC, a China-based company specialized in Antibody-Drug Conjugates (ADC), for the development of new ADC therapeutics, and has commenced product development for Contract Development and Manufacturing Organizati
Lotte Biologics recently announced the signing of a strategic business agreement with NJ Bio, a U.S.-based Contract Research Organization (CRO) specializing in non-clinical and clinical contract research, to provide one-stop Antibody-Drug Conjugate (ADC) services. Established in 2018, NJ Bio, based
Hanmi Pharmaceutical has received additional approval for the therapeutic use of the anti-cancer drug candidate Belvarafenib, which was technologically transferred to global pharmaceutical company Genentech, a member of the Roche Group (RHO).According to the Ministry of Food and Drug Safety on Jan.
Dong-A ST announced on Jan. 10 that it signed a business agreement with Eleven Therapeutics to develop RNA-based gene therapies. The agreement was finalized at the J.P. Morgan Healthcare Conference in San Francisco on Jan. 9.The collaboration will focus on discovering RNA therapies targeting fibroti
Goldman Sachs Asset Management today announced the final close of West Street Life Sciences I, representing the first fund in the firm’s Life Sciences Investing strategy. Life Sciences I closed above its fundraising target, with $650 million in equity commitments from a global, diverse group of inst
Inception Lab,Artificial Intelligence Computer Diagnosis Research Lab in Korea, will receive an innovation award at CES 2024 in Las Vegas, USA, scheduled for January next year.The Consumer Technology Association (CTA), the organizer of CES, evaluates and awards innovation prizes to outstanding produ
Kolmar BNH, a leading Korean health functional food ODM company, is setting its sights on the global market based on world-class manufacturing and quality technology. Notably, HemoHIM, an immune function-improving health functional food developed and manufactured by Kolmar BNH, is elevating the stat
SK bioscience, an innovative vaccine and biotech company committed to promoting human health from prevention to cure, announced that H.E Dr. Jean Kaseya, Director General of Africa CDC visited SK bioscience headquarters on November 3 to discuss collaboration with the Partnerships for African Vaccine
AprilBio revealed on Oct. 5 that they have obtained a U.S. patent for their candidate drug for autoimmune disease treatment, known as “APB-A1” (development code name, partner company Lundbeck code name Lu-AG22515).In October 2021, APB-A1 was exported to Lundbeck, a multinational pharmaceutical compa
GC Biopharma Corp. announced on Oct. 5 that their therapeutic candidate for Thrombotic Thrombocytopenic Purpura (TTP), “GC1126A,” has received a Rare Drug Designation from the U.S. Food and Drug Administration (FDA).As a result of this designation, GC1126A will benefit from tax deductions on researc
Yuhan Pharmaceuticals’ lung cancer drug Leclaza has demonstrated enhanced efficacy when combined with Johnson & Johnson’s (J&J) lung cancer treatment. Detailed data is set to be presented at a global conference on Oct. 23, heightening market anticipation.According to industry sources on Oct. 4, Yuha
Celltrion announced on Oct. 4 that it had obtained additional approval from the U.S. Food and Drug Administration (FDA) for 80mg/0.8mL and 20mg/0.2mL (hereinafter referred to as 80mg and 20mg) dosages of its Humira (active ingredient: adalimumab) biosimilar, Yuflyma (development code: CT-P17), on Se